EuroBiotech: More Articles of Note


> The U.K. is involved in 12% of all cell and gene therapy clinical studies worldwide, according to a new study. Most of the clinical trials have commercial sponsors. Statement 

> Medicxi handed over another tranche of funding to Sosei Heptares’ spinouts Orexia and Inexia as part of its €40 million ($45 million) financing commitment. The investment was triggered by progress at the startups. Release 

> Lava Therapeutics entered into a cell line development agreement with ProBioGen to support development of its T-cell engaging bispecific antibody. Statement 


Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

> Mereo BioPharma presented additional data on its anti-sclerostin antibody setrusumab. The phase 2b results link the drug to dose-dependent increases in bone strength stiffness. Release 

> BerGenBio’s Keytruda combination trial met the criteria needed to advance. The go/no-go decision rested on whether one or more patients responded to the combination. Statement 

> Theranexus outlined plans to begin partnering talks after presenting phase 1b data on Alzheimer’s disease candidate THN201. Release 

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.